Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.

NCT01373151 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.

NCT NCT01373151
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01373151 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB , Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo/Active Controlled Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection With or Without Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Methotrexate.
Lead sponsor
CSL Behring
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
June 30, 2015
Enrollment
418 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis